Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 5.31%
As of Thursday, July 30, Oruka Therapeutics, Inc.’s ORKA share price has surged by 5.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Commentary & Analysis
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 8.04%
As of Friday, July 17, Oruka Therapeutics, Inc.’s ORKA share price has surged by 8.04%, which has investors questioning if this is right time to sell.Michael Rose
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 6.42%
As of Tuesday, July 07, Oruka Therapeutics, Inc.’s ORKA share price has surged by 6.42%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 7.88%
As of Thursday, July 02, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 7.88%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 10.24%
As of Thursday, July 02, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 10.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,116.5 | $269.3 | 70% |
|
| Shares Out (Mil) | 62.9 | 54.0 | 53% |
|
| Institutional Ownership | 97.9% | 93.0% | 76% |
|
| Float (Mil) | 56.9 | 42.2 | 50% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 702 | 473 | 65% |
|
| Price Change (52-week) |
485.8% | 55.9% | 99% |
|
| Growth | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.618) | ($2.366) | ($2.862) | |
| Month Ago EPS | ($0.586) | ($2.283) | ($2.772) | |
| # Rev Up | 1 | 2 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.507) | ($2.037) | ($2.462) | |
| Year/Year Chg | 11.4% | 28.0% | 105.4% | |
| Financials | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($133) | ($43) | 9% |
|
| EPS (TTM) | ($2.024) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($101) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $203 | $2 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $5,991 | $182 | 65% |
|
| Valuation | ORKA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.08 | 2.62 | 79% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (17.8%) | (47.9%) | 21% |
|
| ROE | (18.3%) | (55.0%) | 24% |
|
| Liabilities to Assets | 2.2% | 29.5% | 1% |
|
| F-Score | 4 | 3 | 33% |
|
Oruka Therapeutics, Inc. did not pass any screens on 9/11/2026.
